Ardelyx Inc. Common Stock (NASDAQ:ARDX)

Real-time price: | Most recent change:0.00%

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 14 February 2026

Blog+More

Tony Robbins summarizes several personal finance and investment lessons for the typical layperson.

Charlene Vos

2017-12-21 12:45:00 Thursday ET

Tony Robbins summarizes several personal finance and investment lessons for the typical layperson.

Tony Robbins summarizes several personal finance and investment lessons for the typical layperson: We cannot beat the stock market very often, so it w

+See More

Fed Chair Jay Powell suggests that the recent surge in U.S. business debt poses moderate risks to the economy.

Laura Hermes

2019-06-05 10:34:00 Wednesday ET

Fed Chair Jay Powell suggests that the recent surge in U.S. business debt poses moderate risks to the economy.

Fed Chair Jay Powell suggests that the recent surge in U.S. business debt poses moderate risks to the economy. Many corporate treasuries now carry about 40%

+See More

It can be practical for the U.S. to impose the 2% Warren wealth tax on the rich.

Dan Rochefort

2019-02-03 13:39:00 Sunday ET

It can be practical for the U.S. to impose the 2% Warren wealth tax on the rich.

It can be practical for the U.S. to impose the 2% wealth tax on the rich. Democratic Senator Elizabeth Warren proposes a 2% wealth tax on the richest Americ

+See More

CEO overconfidence and corporate performance

Laura Hermes

2022-11-05 11:32:00 Saturday ET

CEO overconfidence and corporate performance

CEO overconfidence and corporate performance Malmendier and Tate (JFE 2008, JF 2005) argue that overconfident CEOs are more likely to initiate mergers an

+See More

Modern themes and insights in behavioral finance (Part 1)

Laura Hermes

2022-02-05 09:26:00 Saturday ET

Modern themes and insights in behavioral finance (Part 1)

Modern themes and insights in behavioral finance   Shiller, R.J. (2003). From efficient markets theory to behavioral finance. Journal of Economi

+See More

Dallas Federal Reserve Bank President Robert Kaplan expects the U.S. economy to grow at 2.2%-2.5% in 2019-2020.

Becky Berkman

2019-06-11 12:33:00 Tuesday ET

Dallas Federal Reserve Bank President Robert Kaplan expects the U.S. economy to grow at 2.2%-2.5% in 2019-2020.

Dallas Federal Reserve Bank President Robert Kaplan expects the U.S. economy to grow at 2.2%-2.5% in 2019-2020 as inflation rises a bit. In an interview wit

+See More